KT Jerry Yeo, PhD., DABCC, FACB
Professor
Director, Clinical Chemistry Laboratories and UC Med Lab
Contact
Department of PathologyThe University of Chicago
5841 S. Maryland Avenue, MC 0004
Chicago, IL 60637-1470
Phone: (773) 702-1318
Fax: (773) 702-6268
jyeo@bsd.uchicago.edu
Clinical Interest
Dr Jerry Yeo is a board-certified clinical chemist and toxicological chemist with broad expertise in clinical chemistry, therapeutic drug monitoring, toxicology, clinical pharmacogenetics and endocrinology testing.Research Interests
Research focus on new blood biomarkers of cardiac diseases. These include cardiac troponin, BNP and NT-proBNP, and new emerging markers like ischemia-modified albumin, soluble CD40, myeoloperoxidase, etc. In addition, our laboratory is embarking in a new direction in Pharmacogenomics research, involving the genotyping of various Cytochrome P450 polymorphisms and correlating that to the adverse outcomes of certain selected drug regimens.Textbook Publications
- Beisswenger PJ, Szwergold BS, Yeo K-T. Glycated Proteins in Diabetes. In: Goldstein BJ, Gorstein F, eds, Clinics in Laboratory Medicine: Diabetes Mellitus. Philadelphia : W.B. Saunders Co, 2001; pp53-78.
- Yeo KT, Quinn-Hall KS, Bateman SW, Fischer GA, Wieczorek S, Wu AHB. Functional sensitivity of cardiac troponin assays and its implications for risk stratification for patients with acute coronary syndromes. In: Adams III JE, Apple FS, Jaffe AS , Wu AHB, eds. Markers in Cardiology:Current and Future Clinical Application. Armonk , NY :Futura Publ Co. Inc., 2001; pp. 23-30.
- Yeo K-T, Hoefner DM. Interferences in Immunoassays of Cardiac Troponins. In: Wu AHB, ed, Cardiac Markers. Humana Press, 2003; pp187-197.
- Yeo KTJ, Lee HK, Flanagan J. Therapeutic Drug Monitoring and Clinical Toxicology Chapter. In: Wu AHB, ed, Tietz Clinical Guide to Laboratory Tests, W.B. Saunders, 2006; 4th edition.
- Yeo KTJ, Wu AHB, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter Evaluation of the Roche NT-proBNP assay and comparison to Biosite Triage BNP assay. Clin. Chim Acta 2003; 338:107-115
- Panteghini M, Pagani F, Yeo KTJ, Apple FS, Christenson RH, Dati F, Mair J, Ravkilde J, and Wu AHB, on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations. Clin Chem 2004;50: 327-332
- Foote RS, Pearlman JD, Siegel AH, Yeo, KTJ. Detection of exercise-induced ischemia by changes in B-natriuretic peptide. J Am Coll Cardiol 2004;44:1980-1987
- Yeo KTJ, Wong KC, Foote RS. Can exercise-induced changes in B-type natriuretic peptides be used to detect cardiac ischemia? J Cardiac Fail 2005;11(5S):59-64
- Yeo KTJ, Dumont KE, Brough TB. Elecsys NT-pro-BNP and BNP Assays: Are there analytically and clinically relevant differences? J Cardiac Fail 2005;11(5S):84-88
- Lee HK, Lewis LD, Tsongalis GJ, McMullin M, Schur BC , Wong SH, Yeo KTJ. Negative urine opioid screening caused by rifampin mediated induction of oxycodone hepatic metabolism. Clin Chim Acta 2006,367:196-200 (doi:10.1016/j.cca.2005).
- Validation of a CYP2D6 Genotyping assay on Nanochip Ò Molecular Biology Workstation. Lee HK, Lewis LD, Tsongalis GJ, Schur BC, Jannetto PJ, Wong SH, Yeo KTJ. Clin Chem 2007; 53:823-828( doi:10.1373/clinchem.2006.081539)
Selected Publications
The University of Chicago · 5841 S. Maryland Avenue · Chicago, IL 60637
773.702.0647 · webmaster@pathology.bsd.uchicago.edu